Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMA-026
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
IMA-026 is a humanized IgG1 monoclonal antibody designed to bind and neutralize interleukin 13 (IL-13), a cytokine involved in allergic inflammation and immune responses. By targeting IL-13, IMA-026 acts as an interleukin 13 inhibitor, aiming to reduce airway hyperresponsiveness and inflammation associated with asthma. The drug was developed by Wyeth (now part of Pfizer) for the treatment of asthma, but development has not progressed beyond early clinical trials. Its mechanism involves binding non-overlapping epitopes on IL-13 compared to similar antibodies like IMA-638[1][2][4][5][6].
- Other names
- IMA 026IMA026IMA-026
02
Targets
IL-13 (Interleukin-13)
Beyond the preview
Go deeper on IMA-026.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMA-026.